Advertisement

Focus on Transcatheter Aortic Valve Implantation in Low-Risk Patients

  • A. K. Roy
  • B. PrendergastEmail author
Chapter

Abstract

In just more than a decade since the first patients were enrolled in the PARTNER I trial, transcatheter aortic valve implantation (TAVI) has become the treatment of choice for elderly high-risk patients with severe aortic stenosis. Robust randomized trial data from intermediate-risk patient cohorts also support the net superiority of TAVI when undertaken via femoral approach. As the focus now moves to evidence-based treatment of low-risk patients, ongoing trials must address a number of key differentiating features that uniquely define this group of often-younger patients with fewer comorbidities and longer life expectancy. This chapter focuses on the clinical and procedural challenges associated with the percutaneous treatment of the large low-risk cohort of patients with severe aortic stenosis.

Keywords

Transcatheter Aortic stenosis Low-risk Clinical trials Risk score Permanent pacemaker Paravalvular leak Stroke Bicuspid aortic valve Valve durability Leaflet thrombosis 

References

  1. 1.
    Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364(23):2187–98.CrossRefGoogle Scholar
  2. 2.
    Thourani VH, Kodali S, Makkar RR, et al. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet. 2016;387(10034):2218–25.CrossRefGoogle Scholar
  3. 3.
    Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374(17):1609–20.CrossRefGoogle Scholar
  4. 4.
    Sawaya FJ, Spaziano M, Lefevre T, et al. Comparison between the SAPIEN S3 and the SAPIEN XT transcatheter heart valves: a single-center experience. World J Cardiol. 2016;8(12):735–45.CrossRefGoogle Scholar
  5. 5.
    Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363(17):1597–607.CrossRefGoogle Scholar
  6. 6.
    Popma JJ, Adams DH, Reardon MJ, et al. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. J Am Coll Cardiol. 2014;63(19):1972–81.CrossRefGoogle Scholar
  7. 7.
    Adams DH, Popma JJ, Reardon MJ. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014;371(10):967–8.CrossRefGoogle Scholar
  8. 8.
    Reardon MJ, Kleiman NS, Adams DH, et al. Outcomes in the randomized CoreValve US pivotal high risk trial in patients with a society of thoracic surgeons risk score of 7% or less. JAMA Cardiol. 2016;1(8):945–9.CrossRefGoogle Scholar
  9. 9.
    Thyregod HG, Steinbruchel DA, Ihlemann N, et al. Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the all-comers NOTION randomized clinical trial. J Am Coll Cardiol. 2015;65(20):2184–94.CrossRefGoogle Scholar
  10. 10.
    Sondergaard L, Steinbruchel DA, Ihlemann N, et al. Two-year outcomes in patients with severe aortic valve stenosis randomized to transcatheter versus surgical aortic valve replacement: the all-comers nordic aortic valve intervention randomized clinical trial. Circ Cardiovasc Interv. 2016;9(6)Google Scholar
  11. 11.
    Popma JJ, Reardon MJ, Khabbaz K, et al. Early clinical outcomes after transcatheter aortic valve replacement using a novel self-expanding bioprosthesis in patients with severe aortic stenosis who are suboptimal for surgery: results of the Evolut R U.S. study. JACC Cardiovasc Interv. 2017;10(3):268–75.CrossRefGoogle Scholar
  12. 12.
    Maeno Y, Abramowitz Y, Kawamori H, et al. A highly predictive risk model for pacemaker implantation after TAVR. J Am Coll Cardiol Img. 2017;10(10 Pt A):1139–47.CrossRefGoogle Scholar
  13. 13.
    Nazif TM, Dizon JM, Hahn RT, et al. Predictors and clinical outcomes of permanent pacemaker implantation after transcatheter aortic valve replacement: the PARTNER (Placement of AoRtic TraNscathetER Valves) trial and registry. JACC Cardiovasc Interv. 2015;8(1 Pt A):60–9.CrossRefGoogle Scholar
  14. 14.
    Greason KL, Lahr BD, Stulak JM, et al. Long-term mortality effect of early pacemaker implantation after surgical aortic valve replacement. Ann Thorac Surg. 2017;104(4):1259–64.CrossRefGoogle Scholar
  15. 15.
    Meredith IT, Walton A, Walters DL, et al. Mid-term outcomes in patients following transcatheter aortic valve implantation in the CoreValve Australia and New Zealand Study. Heart Lung Circ. 2015;24(3):281–90.CrossRefGoogle Scholar
  16. 16.
    Auffret V, Puri R, Urena M, et al. Conduction disturbances after transcatheter aortic valve replacement: current status and future perspectives. Circulation. 2017;136(11):1049–69.CrossRefGoogle Scholar
  17. 17.
    Urena M, Webb JG, Eltchaninoff H, et al. Late cardiac death in patients undergoing transcatheter aortic valve replacement: incidence and predictors of advanced heart failure and sudden cardiac death. J Am Coll Cardiol. 2015;65(5):437–48.CrossRefGoogle Scholar
  18. 18.
    Frangieh AH, Kasel AM. TAVI in bicuspid aortic valves 'made easy'. Eur Heart J. 2017;38(16):1177–81.CrossRefGoogle Scholar
  19. 19.
    Lansky AJ, Messe SR, Brickman AM, et al. Proposed standardized neurological endpoints for cardiovascular clinical trials: an academic research consortium initiative. J Am Coll Cardiol. 2017;69(6):679–91.CrossRefGoogle Scholar
  20. 20.
    Spaziano M, Sawaya F, Chevalier B, et al. Comparison of systematic predilation, selective predilation, and direct transcatheter aortic valve implantation with the SAPIEN S3 valve. Can J Cardiol. 2017;33(2):260–8.CrossRefGoogle Scholar
  21. 21.
    Haussig S, Mangner N, Dwyer MG, et al. Effect of a cerebral protection device on brain lesions following transcatheter aortic valve implantation in patients with severe aortic stenosis: the CLEAN-TAVI randomized clinical trial. JAMA. 2016;316(6):592–601.CrossRefGoogle Scholar
  22. 22.
    Kapadia SR, Kodali S, Makkar R, et al. Protection against cerebral embolism during transcatheter aortic valve replacement. J Am Coll Cardiol. 2017;69(4):367–77.CrossRefGoogle Scholar
  23. 23.
    Foroutan F, Guyatt GH, O'Brien K, et al. Prognosis after surgical replacement with a bioprosthetic aortic valve in patients with severe symptomatic aortic stenosis: systematic review of observational studies. BMJ. 2016;354:i5065.CrossRefGoogle Scholar
  24. 24.
    Mylotte D, Andalib A, Theriault-Lauzier P, et al. Transcatheter heart valve failure: a systematic review. Eur Heart J. 2015;36(21):1306–27.CrossRefGoogle Scholar
  25. 25.
    Mack MJ, Leon MB, Smith CR, et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015;385(9986):2477–84.CrossRefGoogle Scholar
  26. 26.
    Barbanti M, Petronio AS, Ettori F, et al. 5-Year outcomes after transcatheter aortic valve implantation with CoreValve prosthesis. JACC Cardiovasc Interv. 2015;8(8):1084–91.CrossRefGoogle Scholar
  27. 27.
    Foroutan F, Guyatt GH, Otto CM, et al. Structural valve deterioration after transcatheter aortic valve implantation. Heart. 2017;103(23):1899–905.CrossRefGoogle Scholar
  28. 28.
    Capodanno D, Petronio AS, Prendergast B, et al. Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017;38(45):3382–90.CrossRefGoogle Scholar
  29. 29.
    Chakravarty T, Sondergaard L, Friedman J, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet. 2017;389(10087):2383–92.CrossRefGoogle Scholar
  30. 30.
    Makkar RR, Fontana G, Jilaihawi H, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med. 2015;373(21):2015–24.CrossRefGoogle Scholar
  31. 31.
    Jorgensen TH, Thyregod HG, Tarp JB, et al. Temporal changes of new-onset atrial fibrillation in patients randomized to surgical or transcatheter aortic valve replacement. Int J Cardiol. 2017;234:16–21.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Mater Private HospitalDublinIreland
  2. 2.St Thomas’ HospitalLondonUK

Personalised recommendations